223 related articles for article (PubMed ID: 28017893)
1. Circulating miRNA landscape identifies miR-1246 as promising diagnostic biomarker in high-grade serous ovarian carcinoma: A validation across two independent cohorts.
Todeschini P; Salviato E; Paracchini L; Ferracin M; Petrillo M; Zanotti L; Tognon G; Gambino A; Calura E; Caratti G; Martini P; Beltrame L; Maragoni L; Gallo D; Odicino FE; Sartori E; Scambia G; Negrini M; Ravaggi A; D'Incalci M; Marchini S; Bignotti E; Romualdi C
Cancer Lett; 2017 Mar; 388():320-327. PubMed ID: 28017893
[TBL] [Abstract][Full Text] [Related]
2. Exosomal miR-1290 is a potential biomarker of high-grade serous ovarian carcinoma and can discriminate patients from those with malignancies of other histological types.
Kobayashi M; Sawada K; Nakamura K; Yoshimura A; Miyamoto M; Shimizu A; Ishida K; Nakatsuka E; Kodama M; Hashimoto K; Mabuchi S; Kimura T
J Ovarian Res; 2018 Sep; 11(1):81. PubMed ID: 30219071
[TBL] [Abstract][Full Text] [Related]
3. Extracellular microRNA profiling for prognostic prediction in patients with high-grade serous ovarian carcinoma.
Yoshida K; Yokoi A; Matsuzaki J; Kato T; Ochiya T; Kajiyama H; Yamamoto Y
Cancer Sci; 2021 Dec; 112(12):4977-4986. PubMed ID: 34618992
[TBL] [Abstract][Full Text] [Related]
4. Identification of serum miR-1246 and miR-150-5p as novel diagnostic biomarkers for high-grade serous ovarian cancer.
Niemira M; Erol A; Bielska A; Zeller A; Skwarska A; Chwialkowska K; Kuzmicki M; Szamatowicz J; Reszec J; Knapp P; Moniuszko M; Kretowski A
Sci Rep; 2023 Nov; 13(1):19287. PubMed ID: 37935712
[TBL] [Abstract][Full Text] [Related]
5. miR-106a represses the Rb tumor suppressor p130 to regulate cellular proliferation and differentiation in high-grade serous ovarian carcinoma.
Liu Z; Gersbach E; Zhang X; Xu X; Dong R; Lee P; Liu J; Kong B; Shao C; Wei JJ
Mol Cancer Res; 2013 Nov; 11(11):1314-25. PubMed ID: 24045973
[TBL] [Abstract][Full Text] [Related]
6. Identification of high-grade serous ovarian cancer miRNA species associated with survival and drug response in patients receiving neoadjuvant chemotherapy: a retrospective longitudinal analysis using matched tumor biopsies.
Petrillo M; Zannoni GF; Beltrame L; Martinelli E; DiFeo A; Paracchini L; Craparotta I; Mannarino L; Vizzielli G; Scambia G; D'Incalci M; Romualdi C; Marchini S
Ann Oncol; 2016 Apr; 27(4):625-34. PubMed ID: 26782955
[TBL] [Abstract][Full Text] [Related]
7. Characterization of MicroRNA-200 pathway in ovarian cancer and serous intraepithelial carcinoma of fallopian tube.
Yang J; Zhou Y; Ng SK; Huang KC; Ni X; Choi PW; Hasselblatt K; Muto MG; Welch WR; Berkowitz RS; Ng SW
BMC Cancer; 2017 Jun; 17(1):422. PubMed ID: 28623900
[TBL] [Abstract][Full Text] [Related]
8. Global miRNA expression analysis of serous and clear cell ovarian carcinomas identifies differentially expressed miRNAs including miR-200c-3p as a prognostic marker.
Vilming Elgaaen B; Olstad OK; Haug KB; Brusletto B; Sandvik L; Staff AC; Gautvik KM; Davidson B
BMC Cancer; 2014 Feb; 14():80. PubMed ID: 24512620
[TBL] [Abstract][Full Text] [Related]
9. Meta-analysis of transcriptome reveals let-7b as an unfavorable prognostic biomarker and predicts molecular and clinical subclasses in high-grade serous ovarian carcinoma.
Tang Z; Ow GS; Thiery JP; Ivshina AV; Kuznetsov VA
Int J Cancer; 2014 Jan; 134(2):306-18. PubMed ID: 23825028
[TBL] [Abstract][Full Text] [Related]
10. Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study.
Bagnoli M; Canevari S; Califano D; Losito S; Maio MD; Raspagliesi F; Carcangiu ML; Toffoli G; Cecchin E; Sorio R; Canzonieri V; Russo D; Scognamiglio G; Chiappetta G; Baldassarre G; Lorusso D; Scambia G; Zannoni GF; Savarese A; Carosi M; Scollo P; Breda E; Murgia V; Perrone F; Pignata S; De Cecco L; Mezzanzanica D;
Lancet Oncol; 2016 Aug; 17(8):1137-1146. PubMed ID: 27402147
[TBL] [Abstract][Full Text] [Related]
11. A serum microRNA classifier for early detection of hepatocellular carcinoma: a multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study.
Lin XJ; Chong Y; Guo ZW; Xie C; Yang XJ; Zhang Q; Li SP; Xiong Y; Yuan Y; Min J; Jia WH; Jie Y; Chen MS; Chen MX; Fang JH; Zeng C; Zhang Y; Guo RP; Wu Y; Lin G; Zheng L; Zhuang SM
Lancet Oncol; 2015 Jul; 16(7):804-15. PubMed ID: 26088272
[TBL] [Abstract][Full Text] [Related]
12. HOXA4/HOXB3 gene expression signature as a biomarker of recurrence in patients with high-grade serous ovarian cancer following primary cytoreductive surgery and first-line adjuvant chemotherapy.
Miller KR; Patel JN; Zhang Q; Norris EJ; Symanowski J; Michener C; Sehouli J; Braicu I; Destephanis DD; Sutker AP; Jones W; Livasy CA; Biscotti C; Ganapathi RN; Tait DL; Ganapathi MK
Gynecol Oncol; 2018 Apr; 149(1):155-162. PubMed ID: 29402501
[TBL] [Abstract][Full Text] [Related]
13. Urinary microRNA-30a-5p is a potential biomarker for ovarian serous adenocarcinoma.
Zhou J; Gong G; Tan H; Dai F; Zhu X; Chen Y; Wang J; Liu Y; Chen P; Wu X; Wen J
Oncol Rep; 2015 Jun; 33(6):2915-23. PubMed ID: 25962395
[TBL] [Abstract][Full Text] [Related]
14. Elevated levels of circulating microRNA-200 family members correlate with serous epithelial ovarian cancer.
Kan CW; Hahn MA; Gard GB; Maidens J; Huh JY; Marsh DJ; Howell VM
BMC Cancer; 2012 Dec; 12():627. PubMed ID: 23272653
[TBL] [Abstract][Full Text] [Related]
15. Combining serum microRNA and CA-125 as prognostic indicators of preoperative surgical outcome in women with high-grade serous ovarian cancer.
Shah JS; Gard GB; Yang J; Maidens J; Valmadre S; Soon PS; Marsh DJ
Gynecol Oncol; 2018 Jan; 148(1):181-188. PubMed ID: 29132874
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of ICAM-1 Predicts Poor Survival in High-Grade Serous Ovarian Carcinoma: A Study Based on TCGA and GEO Databases and Tissue Microarray.
Wang S; Yin C; Zhang Y; Zhang L; Tao L; Liang W; Pang L; Fu R; Ding Y; Li F; Jia W
Biomed Res Int; 2019; 2019():2867372. PubMed ID: 31312656
[TBL] [Abstract][Full Text] [Related]
17. Screening of Critical Genes Involved in Metastasis and Prognosis of High-Grade Serous Ovarian Cancer by Gene Expression Profile Data.
Wang R; Du X; Zhi Y
J Comput Biol; 2020 Jul; 27(7):1104-1114. PubMed ID: 31725318
[TBL] [Abstract][Full Text] [Related]
18. A five-DNA methylation signature act as a novel prognostic biomarker in patients with ovarian serous cystadenocarcinoma.
Guo W; Zhu L; Yu M; Zhu R; Chen Q; Wang Q
Clin Epigenetics; 2018 Nov; 10(1):142. PubMed ID: 30446011
[TBL] [Abstract][Full Text] [Related]
19. OCaMIR-A Noninvasive, Diagnostic Signature for Early-Stage Ovarian Cancer: A Multi-cohort Retrospective and Prospective Study.
Kandimalla R; Wang W; Yu F; Zhou N; Gao F; Spillman M; Moukova L; Slaby O; Salhia B; Zhou S; Wang X; Goel A
Clin Cancer Res; 2021 Aug; 27(15):4277-4286. PubMed ID: 34035068
[TBL] [Abstract][Full Text] [Related]
20. Herpes virus microRNA expression and significance in serous ovarian cancer.
Pandya D; Mariani M; McHugh M; Andreoli M; Sieber S; He S; Dowell-Martino C; Fiedler P; Scambia G; Ferlini C
PLoS One; 2014; 9(12):e114750. PubMed ID: 25485872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]